The pathogenesis of pulmonary tuberculosis involves inflammatory mediators reaction,and the pathogenesis of lung cancer is complex,involving multiple genes and molecules.The lung cancer has some relevance with pulmonary tuberculosis in terms of immune abnormalities,antituberculosis drugs,scar repair,chronic inflammation and tuberculin virulence.The treatment of tuberculosis patients with lung cancer is limited to chemotherapy,surgery and radiotherapy.

Objective To Observe the effects of combination regimen of gemcitabine and cisplatin in treating advanced non-small cell lung cancer (NSCLC).Methods 30 patients with advanced NSCLC were treated with GP(GEMZAR 1000mg/m2 d1,8;CDDP 25mg/m2 d1～3 ).The course was repeated every 3 weeks for at least 2 cycles.Results The overall response rate was 36.7%(11/30),whereas 13 patients had stable disease and 6 patients showed progressive disease.The response rate was 46% in untreated patients and 29% was obtained in treated ones.Significant difference was observed between the two groups (P

BACKGROUNDChemotherapy is main treatment of small cell lung cancer (SCLC). This aim of this study is to evaluate the effects and the adverse effects of HCE regimen (hydroxycamptothecin + etoposide + carboplatin) in treatment of SCLC.

METHODSPatients with previously untreated SCLC were randomized into two groups: HCE group (treated by HCE regimen) and EP group (treated by etoposide and cisplatin). The chemotherapeutic effects and the adverse effects were compared between two groups.

RESULTSA total of 71 patients could be evaluated. The overall response rate was 90.3% (28/31) for HCE group with 17 complete response (CR) and 11 partial response (PR), and 70.0% (28/40) in the EP group with 9 CR and 19 PR. The CR was significantly different between two groups. The median survival time of the HCE group and EP group were 11.5 and 25 months respectively. The 1-year survival rate was 72.4% vs 69.4% (P > 0.05), 2-year survival rate was 51.7% vs 44.4% (P < 0.05), and 3-year survival rate was 40.0% vs 29.2% (P < 0.05). Myelosuppression, diarrhea and vomiting were the main toxicities in two groups. The incidence of myelosuppression was higher in the HCE group than that in the EP group but without statistical difference (P > 0.05), whereas the incidence of nausea and vomiting were significantly lower than that in the EP group (P < 0.01).

CONCLUSIONSHCE regimen is an effective regimen for previously untreated SCLC with high CR and slight toxicity. It may be worthy of further clinical investigation.

Objective To investigate the pathogenesis of small cell lung cancer ( SCLC) and to ex-plore the expression of cell cycle related kinase ( CCRK) in SCLC and its clinical significance.Methods Reverse transcription polymerase chain reaction ( RT-PCR) and Western blot were performed to examine ex-pression of CCRK in SCLC and normal tissues.Results The expressions of gene [(0.51 ±0.11)IU/L] and protein [(0.61 ±0.13)IU/L] of CCRK in SCLC tissues were significantly higher than normal tissues [(0.30 ±0.08)IU/L, (0.34 ±0.09)IU/L] ( P <0.05).The expression of CCRK was closely correlated with the clinical curative effect ( P <0.05 ) rather than the clinical stages ( P >0.05 ) .Conclusions The expressions of gene and protein of CCRK in SCLC tissues were significantly higher than normal tissues. CCRK promoted the occurrence and progress of SCLC.Chem can restrain effectually the excessive expres-sion of CCRK.The expressions of gene and protein of CCRK in the different clinical curative effect group had significant difference.

Primary pulmonary synovial sarcoma is a rare pulmonary malignant tumor originated from primitive mesenchymal, which has short overall survival and poor prognosis. Related case reports are lacked at home and abroad. In recent years, the development of targeted therapy has brought remarkable benefits to cancer patients. Apatinib (Hengrui Pharmaceutical Co. Ltd, Jiangsu, People's Republic of China) is a small molecule vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, which selectively inhibits VEGFR-2 and blocks the VEGF signal pathway, then strongly inhibiting the tumor angiogenesis. Apatinib has shown favorable therapeutic effect and acceptable toxicity on various tumors. Here we report a case of primary pulmonary synovial sarcoma with postoperative multiple metastases treated with apatinib, in order to provide a new considerable treatment.
.
Humans ; Lung Neoplasms ; drug therapy ; pathology ; surgery ; Male ; Middle Aged ; Neoplasm Metastasis ; Postoperative Period ; Pyridines ; therapeutic use ; Sarcoma, Synovial ; drug therapy ; pathology ; surgery

BACKGROUND: Primary lung squamous carcinoma that produces alpha-fetoprotein (AFP) is rare and only four related cases have been reported so far. The specific reasons for elevated serum level of AFP and effective treatment regimens for AFP-producing lung squamous carcinoma are not clear. This paper reports the diagnosis and treatment of AFP-producing lung squamous carcinoma so as to provide some references for similar cases in clinical practice. METHODS: The diagnosis and treatment of an AFP-producing lung squamous carcinoma patient admitted to the Shandong Cancer Hospital on October 23, 2020 was retrospectively analyzed, and literatures were reviewed. RESULTS: A 52-year-old male patient was diagnosed as T4N3M0 stage, IIIc right upper lobe lung squamous cell carcinoma with mediastinal lymph node metastasis and multiple metastases in the lung. The main tumor marker was abnormally increased serum AFP. After the rapid progression of two lines chemotherapy, the patient was given anlotinib combined with carrizumab as third-line treatment. The efficacy evaluation reached to partial response (PR) and stable disease (SD) after 2 and 4 cycles of treatment, respectively. The treatment regimen was replaced with albumin paclitaxel plus carrizumab due to gastrointestinal bleeding after the fifth cycle. The patient's condition was under continuous control. CONCLUSIONS The AFP-producing lung squamous carcinoma patient had a good response to anlotinib and immunotherapy in the case report, which may provide some guidances for the clinical practice and the research on AFP-producing lung squamous carcinoma.
Carcinoma, Non-Small-Cell Lung ; Carcinoma, Squamous Cell/drug therapy* ; Humans ; Lung ; Lung Neoplasms/drug therapy* ; Male ; Middle Aged ; Retrospective Studies ; alpha-Fetoproteins

In recent years, research on immunotherapy has made great progress. Currently, immunotherapy has made significant breakthrough, especially programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors (e.g, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab and Avelumab, etc.) have brought clinical benefits to patients with various pathological types of lung cancer, including squamous cell carcinoma, adenocarcinoma and small cell lung cancer. In this paper, the application value and current status of PD-1/PD-L1 checkpoint inhibitors in lung cancer were comprehensively analyzed by reviewing and interpreting representative clinical studies. Based on the results of various large-scale clinical trials results, the indications of immunotherapy in lung cancer have been continuously broadened, and the details of immunotherapy have also been constantly optimized. However, immunotherapy still faces many challenges, such as the selection of immune combination strategies, the exploration of biomarkers, the management of adverse events, the feasibility of application of driver gene mutation population and so on. In this article, we made a systematic review about the latest progress of PD-1/PD-L1 checkpoint inhibitors in lung cancer, in order to provide cutting-edge reference for the clinical workers.
.
Animals ; Antineoplastic Agents, Immunological ; therapeutic use ; B7-H1 Antigen ; antagonists & inhibitors ; genetics ; immunology ; Humans ; Immunotherapy ; Lung Neoplasms ; drug therapy ; genetics ; immunology ; Programmed Cell Death 1 Receptor ; antagonists & inhibitors ; genetics ; metabolism

BACKGROUND: Programmed cell death 1 or programmed cell death ligand 1 inhibitor (PD-1/PD-L1 inhibitor) and docetaxel, as the standard second-line treatments of advanced non-small cell lung cancer (NSCLC) patients, have limited effects. There are few studies on whether docetaxel combined with PD-1/PD-L1 inhibitor can increase the efficacy and make patients better benefit. The aim of this study is to evaluate the efficacy and safety of docetaxel combined with PD-1/PD-L1 inhibitor for the second-line treatment of stage IV NSCLC patients. METHODS: Stage IV NSCLC patients (n=118) who received treatment at Shandong Cancer Hospital between October 1, 2018, and December 31, 2020, were retrospectively analyzed. They were divided into observation group (n=69) and control group (n=49) according to different treatment plan. Observation group was given docetaxel plus PD-1/PD-L1 inhibitor, while control group was given PD-1/PD-L1 inhibitor. The clinical curative effect and the incidence of adverse reactions of grade 3 and above were compared between the two groups. RESULTS: The disease control rate (DCR) was higher in the observation group (89.9%) than that in the control group (73.5%) (P=0.019), and the objective response rate (ORR) showed no significant difference between observation group (24.6%) and control group (16.3%) (P=0.276). Till June 22, 2021, the 1-year PFS rate showed no difference between observation group (16.5%) and control group (7.7%) (P=0.205). During the treatment period, the adverse reactions of the two groups were mostly grade 1 to 2, and could be tolerated. The incidence of bone marrow suppression in observation group was higher than that in the control group (P<0.05), and the remaining adverse reactions were not statistically different from control group. Cox regression analysis showed that performance status (PS) (P=0.020) and age (P=0.049) were independent prognostic factors for the effect of docetaxel combined with PD-1/PD-L1 inhibitor. CONCLUSIONS The second-line treatment with docetaxel plus PD-1/PD-L1 inhibitor in patients with stage IV NSCLC can improve the DCR and prolong the PFS, and the adverse reactions are tolerable.